Bladder Cancer
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG) Protocol number: 42756493BLC3005
- Details
ClinicalTrials.gov ID:
NCT06919965
Diagnosis Type:
NA
USOR Number:
- Address
,
P: